As with any medicine, the MHRA will keep the safety and effectiveness of zapomeran under close review.
Similar Posts
MHRA and NICE invite early adopters to trial accelerated aligned pathway – six months ahead of schedule
Aligned pathway will streamline decisions on licensing and value for medicines, helping patients to benefit from them sooner.
Notice: Medicines: terminated and cancelled manufacturing and wholesale dealer licences
UK companies who have their licence to manufacture or wholesale medicines terminated and cancelled.
MHRA MedRegs blog – Summer 2025
Updates on regulatory reform and plans to support innovation.
Clinical trials for medicines: ending a clinical trial
Guidance on the process for ending a clinical trial.
Clinical trials for medicines: notifiable trials
Guidance on categorising certain clinical trials as ‘notifiable’.
Transparency data: MHRA Performance Data
Performance data for MHRA key performance indicators (KPIs) and information on the expected timeline to complete a specific regulatory function.